I'd like to hear from business-savvy investors about what they think about Friday's shelf offering. So far, it seems to be a positive event per these 2 media outlets:

GuruFocus News:
"For investors, CytoDyn's mixed securities shelf registration offers a dynamic opportunity to engage with a company at the forefront of biotechnological innovation."

AInvest:
"Cytodyn's $100 million mixed shelf filing is more than a financial maneuver; it's a vote of confidence in its pipeline and leadership's ability to navigate the biotech landscape."

However, I was assuming/hoping that our immediate and long-term financing was about to come from a partnership.

Does the shelf offering make us more (or less) attractive to a potential partner? Does the shelf offering imply we're willing (or planning) to go this alone?

All opinions welcome, Thanks!